New models for defining prostate cancer biology and patient prognosis

• 作者: James Brundage Benjamin L Maughan
• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2022,（1）
• 所属期刊栏目: COMMENTARY
• 页码范围: 119-120
• 页数: 2页
• 语种: 英文
• DOI: 10.4103/aja.aja_48_21

摘要

Currently,the prognosis of patients with metastatic prostate cancer is most commonly defined by clinical factors including performance status,presence of visceral metastasis,lactate dehydrogenase level,opioid analgesic use,albumin level,presence of anemia,prostate-specific antigen level,and alkaline phosphatase level(i.e.,Halabi model).1 This model is most commonly used in the current prospective clinical trials today.However,it is only an inference of the underlying biology and not a direct measurement of that biology.